← All trials
NCT05056402
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 19, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2023
- First posted
- Sep 24, 2021
- Last posted
- Oct 5, 2021
- Enrollment
- 1382
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Xiamen UniversityLead sponsor
- Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.Collaborator
- Xiamen UniversityReponsible party - principal investigator
- Xiamen UniversityStudy chair
- Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.Collaborator
- Government of ChinaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.